New Prescriptions: Innovation in the Treatment of Diseases and Infections to be held April 20, 2016 in New York, NY
BEDMINSTER, NJ / ACCESSWIRE / April 6, 2016 / CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced that the Company's Chief Executive Officer, Randy Milby, will participate in a panel discussion titled, "Showcase of Novel Technologies in Fighting Infections," as part of FBR & Company's New Prescriptions: Innovation in the Treatment of Diseases and Infections, on April 20, 2016, in New York.
Randy Milby, CorMedix CEO, said, "We are honored to be invited to participate in this important discussion about novel approaches to fighting infections. Our unique non-antibiotic anti-infective solution Neutrolin® has been proven to reduce bloodstream infections following venous catheter placement, which cost an average of $45,000 per infection and an estimated $2.3 billion annual cost to the U.S. healthcare system. To put it in perspective, this accounts for more than 20% of the total annual cost of hospital-acquired infections. We've also demonstrated recently that the active anti-microbial component of Neutrolin, taurolidine, can be effectively incorporated into various medical and surgical materials to prevent infection-related complications and further damage to vulnerable tissues. We are proud of our innovations and look forward to sharing our insights on this panel."
Please contact your FBR representative for more information. Should you require further information, please contact the FBR Conference and 1on1 Desk (1on1@fbr.com).
About CorMedix Inc.
CorMedix Inc. is an emerging commercial-stage biopharmaceutical company that initiated a Phase III clinical study of a novel anti-infective solution, Neutrolin, in hemodialysis patients in the United States in December 2015. The Company seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of infectious and inflammatory diseases. CorMedix's first commercial product in Europe is Neutrolin®, a catheter lock solution for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used for vascular access in hemodialysis patients, in addition to oncology patients, critical care patients, and patients receiving total parenteral nutrition, IV hydration, and/or IV medications. The FDA has granted Fast Track status to Neutrolin Catheter Lock Solution and also has designated Neutrolin as a Qualified Infectious Disease Product for oncology, hemodialysis, and critical care/intensive care patients, where catheter-related blood stream infections and clotting can be life-threatening. The initial and planned indications aim to address significant needs in catheter-based treatments in the U.S. and the rest of the world. For more information visit: www.cormedix.com.